Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Orgenesis's Total Stockholders Equity for the quarter that ended in Dec. 2021 was $38.49 Mil. Orgenesis's Total Assets for the quarter that ended in Dec. 2021 was $59.84 Mil.
Therefore, Orgenesis's Equity to Asset Ratio for the quarter that ended in Dec. 2021 was 0.64.
The historical rank and industry rank for Orgenesis's Equity-to-Asset or its related term are showing as below:
ORGS'
s Equity-to-Asset Range Over the Past 10 Years
Min: -41.5 Med: 0.21 Max: 0.95
Current: 0.64
During the past 13 years, the highest Equity to Asset Ratio of Orgenesis was 0.95. The lowest was -41.50. And the median was 0.21.
ORGS's Equity-to-Asset is ranked worse than 63.32% of 1554
companies
in the Biotechnology industry
Industry Median: 0.75
vs ORGS: 0.64
Orgenesis Equity-to-Asset Historical Data
The historical data trend for Orgenesis's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Equity-to-Asset
0.35
0.38
0.06
0.68
0.64
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Equity-to-Asset
0.68
0.66
0.68
0.66
0.64
Competitive Comparison
For the Biotechnology subindustry, Orgenesis's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orgenesis Equity-to-Asset Distribution
For the Biotechnology industry and Healthcare sector, Orgenesis's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Orgenesis's Equity-to-Asset falls into.
Orgenesis Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Orgenesis's Equity to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (NAS:ORGS) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Orgenesis Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Orgenesis's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.01(0.47%) Volume: 226,718 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
